Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2017-06-06 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes the entry into material definitive agreements (license agreements) with City of Hope, including details about upfront fees, milestone payments, royalties, and termination clauses. There are no financial statements or quarterly/yearly financial results presented. The document is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a significant corporate event (license agreements). Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 7357 characters, which is sufficient to contain substantive information rather than just an announcement or certification.
2017-06-06 English
SC 13D
Major Shareholding Notification
2017-05-26 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-05-15 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-28 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 24, 2017, by Mustang Bio, Inc. The content focuses on the appointment of a new President and CEO, Manuel Litchman, including details about his background, employment agreement, and compensatory arrangements. The key section is Item 5.02, which relates to the departure and appointment of directors or certain officers. There is no financial data or report content, but rather an announcement of management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not a full financial report, earnings release, or regulatory filing of another type. Therefore, the correct classification is MANG with high confidence.
2017-04-24 English
Regulatory Filings 2017
Regulatory Filings
2017-04-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.